News Releases

- El nuevo análisis de la procalcitonina de Beckman Coulter ayuda al facultativo a determinar qué pacientes se encuentran en riesgo de evolucionar al estado de choque séptico El Access PCT...

Das umfangreichste Portfolio in der Branche für In-vitro-Diagnostiktests zur Erkennung und zum Management von Sepsis wird nun durch Access PCT verstärkt. BREA, Kalifornien, 26. März 2019...

Access PCT strengthens industry’s most extensive portfolio of in-vitro diagnostic testing for sepsis identification and management BREA, Calif. — (March 26, 2019) — Beckman Coulter, a global...

Beckman Coulter, a global leader in clinical diagnostics, announced today that its DxH 520 hematology analyzer has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), and...

Le nouveau test a obtenu le marquage CE et une autorisation 501(k) de la FDA américaine BREA, Californie, 7 mars 2019 /PRNewswire/ -- Beckman Coulter, leader mondial dans le secteur du diagnostic...

Neuer Assay erhält CE-Kennzeichnung und U.S. FDA 501(k)-Zulassung BREA, Kalifornien, 7. März 2019 /PRNewswire/ -- Beckman Coulter, ein weltweit führender Anbieter in der klinischen Diagnostik,...

- El ensayo avanzado de HbA1c de Beckman Coulter permite a los médicos realizar un diagnóstico más preciso de pacientes con diabetes El nuevo ensayo obtiene la certificación de marcado CE y la...

Beckman Coulter, a global leader in the clinical diagnostics industry, today announced the latest addition to its comprehensive chemistry assay menu—the fully automated hemoglobin A1c (HbA1c)...

Beckman Coulter today announced the U.S. release of its DxONE Workflow Manager, the first and only cloud-based middleware offered by a major in-vitro diagnostics organization, designed to help...

Beckman Coulter, a global leader in the clinical diagnostics industry, today announced it is joining forces with Sepsis Alliance, the nation's leading sepsis organization, to support the Sepsis...

Beckman Coulter announced today commercialization of DxONE Inventory Manager, its automated, cloud-based software technology that simplifies inventory management and enhances operational...

Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, is embarking on an innovation collaboration with Johns Hopkins Medicine to explore co-innovation initiatives with...

Featuring innovative technology, these diagnostic tools will help enhance analysis and detection for critical blood-based conditions and diseases for patients across the country BREA, Calif.,...

Beckman Coulter today announced the release of its newest software version for the company's flagship middleware system, REMISOL Advance. The software iteration features enhancements—designed in...

Beckman Coulter, a global leader in the clinical diagnostics industry, announced today that it is a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the...

Beckman Coulter announced today commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing for microbiology...

Beckman Coulter and U.S. ARKRAY, Inc. (ARKRAY) announced a new partnership and the launch of the iQ Urinalysis Workcell. The iQ Workcell pairs two of the world's most highly regarded automated...

Beckman Coulter Diagnostics goes beyond technology to help laboratories face challenges in the current healthcare environment BREA, Calif. — (July 20, 2018) — Beckman Coulter, a global leader...

Beckman Coulter Diagnostics announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new high-sensitivity troponin (hsTnI) assay, Access hsTnI, for...

New assay enables hospitals to provide efficiency improvements in cardiac patient management BREA, Calif. — (June 26, 2018) — Beckman Coulter Diagnostics announced today that it has received...

Beckman Coulter announced that it has filed a submission for 510(k) clearance with the U.S. Food and Drug Administration (FDA) for its Early Sepsis Indicator. The first-of-its-kind...

Agreement to focus on accelerating campus innovation from lab to real world via UCI Applied Innovation IRVINE, Calif. — (June 21, 2018) — Beckman Coulter Diagnostics, a global leader in the...

The new Access Sensitive Estradiol assay completes the comprehensive reproductive menu for Access immunoassay systems and provides better operational efficiency while delivering quality results....

Beckman Coulter announced today the positive results of a clinical trial suggesting that blood tests may offer key benefits in the initial screening for obstructive sleep apnea. The study, which...

Software version 2 enhancements improve flagging and streamline the quality control processes BREA, Calif. — (May 10, 2018) — Beckman Coulter Diagnostics announced today the global launch of...

First-of-its-kind hematology-based test intended to alert emergency department clinicians to the possibility of sepsis or risk of developing sepsis as part of a routine CBC with differential test...

Beckman Coulter announced today the release of the DxH 900 hematology analyzer, giving mid- to high-volume clinical laboratories the ability to perform complete blood count and white blood cell...

BREA, Calif. — (April 18, 2018) — Beckman Coulter Diagnostics announced achievement of CE Mark of its DxH 520 hematology analyzer, designed to help physician office laboratories deliver...

Beckman Coulter, a global leader in the clinical diagnostics industry, today announced its exclusive sponsorship of the ESCAVO Sepsis Clinical Guide (Sepsis app), a point-of-care medical reference...

Beckman Coulter Diagnostics today announced commercialization of its Access Sensitive Estradiol in the U.S., with simultaneous commercial availability of its assay in the majority of global...

BALLINA, Co. Tipperary (Ireland) and BREA, Calif. (USA) – (March 15, 2018) — Long-term agreement expands Beckman Coulter customers’ access to high-quality QC products, supporting efficient...

Fully contained automation solution boosts laboratory productivity, workflow flexibility and testing quality BREA, Calif. — (Feb. 20 2018) — Beckman Coulter Diagnostics and NTE-SENER, the...

Beckman Coulter Diagnostics today announced the addition of 6-Acetylmorphine (6-AM) and Buprenorphine (BUP) assays to its broad menu of drugs-of-abuse tests that meet the demands of onsite testing...

Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic (IVD) use in the U.S. This simple test aids healthcare providers in the...

A Beckman Coulter assumiu o compromisso de garantir aos clientes o recebimento de ensaios da mais alta qualidade, a tempo, para ajudar os profissionais de saúde e de laboratórios a oferecer...

Beckman Coulter ist fest entschlossen, seinen Kunden weiterhin erstklassige Assays zeitgerecht bereitzustellen, damit Ärzte und Labors ihre Patienten besser versorgen können. Zu diesem Zweck...

Beckman Coulter apuesta por que sus clientes puedan disponer a tiempo de análisis de la mayor calidad posible con el fin de contribuir a que los profesionales sanitarios y de laboratorio sean...

Beckman Coulter s'engage à garantir que ses clients bénéficient des tests de la plus haute qualité, dans les délais, afin d'aider les professionnels de santé et de laboratoire à fournir de...

Beckman Coulter is committed to ensuring customers receive the highest quality assays, on-time, to help healthcare and laboratory professionals provide better patient care. To further these goals,...

A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when phi testing was included in their overall, routine, clinical assessment.

Un nouveau dosage permet aux hôpitaux d'améliorer de façon efficace la gestion des patients cardiaques BREA, Californie, 7 novembre 2017 /PRNewswire/ -- Beckman Coulter Diagnostics a annoncé...

La nueva prueba permite a los hospitales proporcionar una mejora en la gestión eficaz de los enfermos cardiacos BREA, California, 7 de noviembre de 2017 /PRNewswire/ -- Beckman Coulter...

Krankenhäuser können mit neuem Assay Effizienzverbesserungen im Herzpatientenmanagement erzielen BREA, Kalifornien, 7. November 2017 /PRNewswire/ -- Beckman Coulter Diagnostics gab heute...

New assay enables hospitals to provide efficiency improvements in cardiac patient management BREA, Calif. —(Nov. 7, 2017) — Beckman Coulter Diagnostics announced today that it has received CE...

Beckman Coulter Diagnostics is pleased to announce worldwide availability of the Access 2 immunoassay system with enhanced features. Built upon a 20-year legacy of reliable and efficient...

Beckman Coulter Diagnostics introduces its DxONE information management solutions, an integrated system of technologies and capabilities, designed to ease data access and usability. DxONE is...

Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry will present its global initiative, "Partnering Today for a Stronger Tomorrow," at the 69th American Association...

Beckman Coulter Diagnostics along with partner Diazyme Laboratories announces FDA clearance of a new procalcitonin (PCT) assay, an important tool for the management of bacterial infections and sepsis.

Organization also premieres a suite of new products designed to improve operational efficiency and drive clinical excellence. NYON, Switzerland—(June 12, 2017) — Today at the 22nd IFCC-EFLM...

Automated chemistry assay offers a tool for the diagnosis and management of life-threatening bacterial sepsis BREA, Calif. — (April 20, 2017) — Beckman Coulter Diagnostics announced a...